Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.
Outcomes in patients with hrTA-TMA treated with eculizumab. Survival in HSCT recipients with hrTA-TMA treated with the terminal complement blocker eculizumab was calculated using Kaplan–Meier and log-rank tests starting at the beginning of HSCT (day 0, stem cell infusion day). (A) One-year post-HSCT survival in all treated patients was 66%. (B) One-year post-HSCT survival in patients with GI bleeding and without was 44% vs 78% (P = .01).
